Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalating treatment regimens for intermediate- and high-risk oropharyngeal cancer
ISRCTN41478539Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- May 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cisplatin, docetaxel, fluorouracil and durvalumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Birmingham. Started May 2015; status: completed.
02
Drugs
cisplatindocetaxelfluorouracildurvalumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ISRCTN41478539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41478539.